Date: 2014-02-17
Type of information: R&D agreement
Compound: Polyethylenimine (PEI) for in vitro transfection applications
Company: Polyplus-transfection (France) NIH (USA)
Therapeutic area: Technology - Services
Type agreement: R&D
licensing
Action mechanism:
Disease:
Details: * On February 17, 2014, Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, has announced that it has granted two agencies of the United States National Institutes of Health (“NIH”) a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases (“NIAID”) and the National Cancer Institute (“NCI”). The NIAID and the NCI, by entering into this license agreement, become two of Polyplus’ sub-licensees who have acquired rights to use of PEI-mediated transfection applications for research purposes. The license provides the NIAID and the NCI with freedom to use this globally recognized high performance technology, from Polyplus-transfection, in its research to produce transfected cells, proteins, viruses and antibodies.
Financial terms: Financial terms were not disclosed.
Latest news:
